|
Safety and Efficacy of Belzutifan in Preoperative Preparation for Patients With Pheochromocytoma/Paraganglioma (PPGL)
RECRUITINGPhase 4Sponsored by Longfei Liu,MD
Actively Recruiting
PhasePhase 4
SponsorLongfei Liu,MD
Started2026-04-01
Est. completion2027-12-31
Eligibility
Age14 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07907341
Summary
It is preliminarily clarified that belzutifan exerts an inhibitory effect on catecholamine synthesis in pheochromocytoma and paraganglioma (PPGL), and its safety is simultaneously confirmed, thereby providing preliminary experimental results for the further exploration of belzutifan as a perioperative preparation drug for patients with PPGL.
Eligibility
Age: 14 Years – 85 YearsHealthy volunteers accepted
Inclusion Criteria: 1. Aged 14 to 85 years. 2. Adrenal pheochromocytoma or retroperitoneal paraganglioma suspected based on imaging and biochemical diagnoses. 3. Scheduled for surgical treatment. 4. American Society of Anesthesiologists (ASA) physical status classification of Grade Ⅰ to Ⅲ. 5. Informed consent obtained from the patient or their legal guardian. 6. Confirmed non-pregnant and non-lactating status. 7. Laboratory requirements: * Absolute Granulocyte Count (AGC) \> 1.5 × 10⁹/L; * Platelet count \> 80 × 10⁹/L; * Hemoglobin (Hb) \> 90 g/L; * Serum bilirubin \< 1.5 × the upper limit of normal (ULN); * Serum creatinine \< 1.5 × ULN or creatinine clearance \>= 60 mL/min; * Negative serum human chorionic gonadotropin (hCG) test result. 8. Capacity to understand the study and willingness to sign a written informed consent form. Exclusion Criteria: 1. Incapable of correctly understanding the content of questionnaires and unable to cooperate with researchers. 2. Receiving other anti-tumor drug therapies. 3. Pregnant or lactating women, and men or women of childbearing age who refuse to take appropriate contraceptive measures. 4. A history of allergic reactions to belzutifan or hypoxia-inducible factor (HIF) inhibitors. 5. Presence of multiple factors affecting oral drug administration (e.g., dysphagia, chronic diarrhea, intestinal obstruction, etc.) or other conditions interfering with medication intake. 6. Severe myelosuppression or coagulation abnormalities (International Normalized Ratio (INR) \> 1.5, or Prothrombin Time (PT) \> upper limit of normal (ULN) by 4 seconds, or Activated Partial Thromboplastin Time (APTT) \> 1.5 × ULN), a bleeding tendency, or ongoing thrombolytic or anticoagulant therapy. 7. A history of treatment with other HIF inhibitors. 8. Prior receipt of chemotherapy, targeted therapy, biological agents, or other investigational treatments within the 4 weeks prior to the first administration of the study intervention. 9. Active or uncontrolled comorbid diseases, including but not limited to: * Uncontrolled myocardial ischemia or myocardial infarction, cardiac arrhythmias (including corrected QT interval (QTc) \>= 480 ms), and uncontrolled congestive heart failure of New York Heart Association (NYHA) Grade \>= 2; * Clinically significant heart disease, including unstable angina pectoris, acute myocardial infarction, or a history of Coronary Artery Bypass Grafting (CABG) or Percutaneous Transluminal Coronary Angioplasty (PTCA) within 6 months prior to study enrollment, or congestive heart failure of NYHA Grade Ⅲ or Ⅳ; * Persistent or active infection; * Liver cirrhosis, decompensated liver disease, active hepatitis, or chronic hepatitis requiring antiviral therapy; * Renal failure requiring hemodialysis or peritoneal dialysis; * A history of immunodeficiency, including Human Immunodeficiency Virus (HIV) infection or other acquired/congenital immunodeficiency diseases, or a history of organ transplantation. 10. A history of seizures requiring medical treatment. 11. Occurrence of any of the following conditions within 6 months prior to study registration: Cerebrovascular Accident (CVA) or Transient Ischemic Attack (TIA); severe or unstable cardiac arrhythmia; pulmonary embolism or untreated Deep Venous Thrombosis (DVT). 12. A history of psychoactive substance abuse with inability to abstain, or presence of mental disorders. 13. Concomitant use of drugs that interact with belzutifan. 14. Patients with stable disease who decline surgical treatment. 15. Resting pulse oximetry reading \< 92%, or requirement for intermittent oxygen supplementation, or long-term oxygen therapy.
Conditions2
CancerPheochromocytoma and Paraganglioma (PPGL)
Interventions1
Related trials
- An Experimental Study of Belzutifan Impact on Catecholamine Metabolism — Cambridge University Hospitals NHS Foundation Trust
- Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial — José Claudio Casali da Rocha
- A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) — Merck Sharp & Dohme LLC
- A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma — HiberCell, Inc.
- Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) — Merck Sharp & Dohme LLC
- Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) — Merck Sharp & Dohme LLC
- A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) — Merck Sharp & Dohme LLC
- A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01) — Merck Sharp & Dohme LLC
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 4
SponsorLongfei Liu,MD
Started2026-04-01
Est. completion2027-12-31
Eligibility
Age14 Years – 85 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07907341